Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Montana5on Jun 07, 2020 2:59pm
286 Views
Post# 31121969

Holdings

HoldingsI'm going to focus on Legault and Wallace only. Legault converted 1.75mm options (approximately 34% of his balance) between 14.5-33 cents, leaving a balance of 3,380,206 options. He then sold all 1.75mm of the newly converted shares for between 60 and 61 cents, leaving him a direct balance of 300,000 common shares. He also indirectly owns 296,660 shares. He has 6.79mm RSUs and 57,500 warrants.

Wallace converted 2.5mm options (approximately 45% of his balance) between 14-33 cents, leaving a balance of 3.1mm options. He then sold all 2.5mm of the newly converted shares for 60 cents, leaving him a direct balance of 276,770 common shares. He also indirectly sold 225,000 common shares leaving him a balance of 400,000 shares owned indirectly. He has 6.05mm RSUs and no warrants.

Can you blame these two for selling? No. In the end, if the company is acquired, why not take a little off the top now because upon a future sale, the options, RSUs and warrants mean nothing. Optically, it is puzzling in spite of the recent Phase 2 results. But it does make sense if a future sale is immenent. The hiring of Batal (Commercial Strategy) and Stauffer (CMO) was for a purpose. If you truly believe in the potential of this company, I wouldn't worry about Legault and Wallace reaping some long awaited benefits.

Bullboard Posts